Pegylated interferons

References

• Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci 1987;147:258–67
   Google Scholar
• The Italian Co-operative Study Group on Chronic Myeloid Leukaemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 1994;330:820–5
   PubMed Web of Science ®Google Scholar
• Carr DJ, Noisakran S. the anitiviral efficacy of the murine alpha-1-interferon transgene against ocular herpes simplex virus type 1 requires the presence of CD4 (+) alpha/beta T-cell receptor- positive T lymphocytes with the capacity to produce gamma interferon. J Virol 2002:76;9398–406
   Google Scholar
• Nakajima Y, Kuwata T, Tomita Y, et al. Effect of interferon on the production of HbsAg and induction of an antiviral state in human hepatoma cell line PLC/PRF/5. Microbiol Immunol 1982;26:705–12
   Google Scholar
• Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon: a preliminary report. N Engl J Med 1986;315:1575–8
   PubMed Web of Science ®Google Scholar
• Hutchison JG, Gordon SC, Schiff ER, et al. Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998;339:1485–92
   Google Scholar
• Foster G, Goldin R, Main J, et al. The management of chronic hepatitis C: clinical audit of a biopsy based management algorithm. Br Med J 1997;315:453–8
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with inter-feron alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy R, et al. Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002:347:975-82
   Google Scholar
• Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alfa2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group. Lancet 1998;352:1426–32
   Google Scholar
• Mangia A, Santoro R, Piattelli M, et al. High doses of interferon in combination with ribavirin are more effective than the standard regimen in patients with HCV genotype chronic hepatitis. J Hepatology 2002;37:151–3
   Google Scholar
• Berg T, Hoffmann RM, Teuber G, et al. Efficacy of a short-term ribavirin plus interferon alpha combination therapy followed by interferom alpha alone in previously untreated patients with chronic hepatitis C: a randomised multi-center trial. Liver 2000;20:427–36
   Google Scholar
• Lam NP, Neumann AU, Gretch DR, et al. Dose dependent acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997:26:226-31
   Google Scholar
• Prince AM, Brotman B, Grady GF, et al. Long-incubation post-transfusion hepatitis without serological evidence of exposure to hepatitis B virus. Lancet 1974;2:241–6
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner AJ, et al. Isolation of a cDNA clone derived from a blood borne non-A, non-B viral hepatitis clone. Science 1989:244;359–61
   Google Scholar
• Zanetti AR, Tanzi E, Paccagnini S, et al. Mother to infant transmission of HCV. Lancet 1995;345:273–9
   PubMed Web of Science ®Google Scholar
• Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997;349:825–32
   PubMed Web of Science ®Google Scholar
• Tong MJ, El-Farra NS, Reikes AR, et al. Clinical outcomes after transfusion associated hepatitis C virus. N Engl J Med 1995;332:1463–6
   PubMed Web of Science ®Google Scholar
• Alter MJ, Kruszon-Moron D, Nainon OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New Engl J Med 1999;341;556-62
   Google Scholar
• Armstrong GL, Alter MJ, McQuillan GM, et al. The past incidence of hepatitis C virus infection: implications for the future burden of chronic liver disease in the United States. Hepatology 2000;31:777–82
   PubMed Web of Science ®Google Scholar
• Zou S, Tepper M, El Saadany S.Prediction of hepatitis C burden in Canada. Can J Gastroenterology 2000;14:575–80
   PubMed Web of Science ®Google Scholar
• Report of a WHO Consultation organised in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. Global surveillance and control of hepatitis C. J Viral Hep 1999;6:35–47
   Google Scholar
• Abuchowski A, Van Es T, Palczuk NC, et al. Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 1977:252:3578-81
   Google Scholar
• Abuchowski A, McCoy JR, Palczuk NC, et al. Effect of covalent attachment of polyethylene glycol on immunogenecity and circulating life of bovine liver catalase. J Biol Chem 1977;252:3582–6
   PubMed Web of Science ®Google Scholar
• Savoca KV, Abuchowski A, Van Es T, et al. Preparation of a non-immunogenic arginase by the covalent attachment of polyethylene glycol. Biochem Biophys Acta 1979;578:47–53
   Google Scholar
• Kozlowski A, Charles SA, Harris JM. Development of pegylated interferons for the treatment of chronic hepatitis C. BioDrugs 2001:15:419-29
   Google Scholar
• Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother 2000;34:915–23
   PubMed Web of Science ®Google Scholar
• Luxon BA, Grace M, Brassard D, et al. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin Ther 2002;24:1363–83
   PubMed Web of Science ®Google Scholar
• Hershfield MS, Buckley RH, Greenberg ML, et al. Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. New Engl J Med 1987;316:589–96
   PubMed Web of Science ®Google Scholar
• Barouki FM, Witter FR, Griggin DE. Time course of interferon levels, antiviral state, 2',5'-oligoadenylate synthetase and side effects in healthy men. J Interferon Res 1987;7(Suppl 1):29–39
   Google Scholar
• Perry CM, Jarvis B. Peginterferon-alpha-2a (40kD): a review of its use in the management of chronic hepatitis C. Drugs 2001;61:2263–88
   PubMed Web of Science ®Google Scholar
• Intron(r)-A. Product Information
   Google Scholar
• Roferon(r)-A. Product Information
   Google Scholar
• Xu Z-X, Hoffman J, Patel I, et al. Single-dose safety/ tolerability and pharmacokinetic/pharmacodynamics (PK/ PD) following administration of ascending subcutaneous doses of pegylated-interferon (PEG-IFN) and interferon a-2a to healthy subjects. Hepatology 1998;28:702A
   Google Scholar
• Lam NP, Neumann AU, Gretch DR, et al. Dose dependant acute clearance of hepatitis C genotype 1 virus with interferon alfa. Hepatology 1997;26:226–31
   PubMed Web of Science ®Google Scholar
• Pawlotsky JM, Dahari H, Neumann AU, et al. Antiviral action of ribavirin in chronic hepatitis C. Gastroenterology 2004;126:703–14
   PubMed Web of Science ®Google Scholar
• Grace M, Youngster S, Gitlin G, et al. Structural and biologic characterization of pegylated recombinant IFNalpha2b. J Interferon Cytokine Res 2001;21:1103–15
   PubMed Web of Science ®Google Scholar
• Wang YS, Youngster S, Bausch J. Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry 2000;39:10634–40
   PubMed Web of Science ®Google Scholar
• PegIntron(r). Product Information
   Google Scholar
• Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon alpha-2a for the treatment of hepatitis C. Bioconjug Chem 2001;12:195–202
   PubMed Web of Science ®Google Scholar
• PEGASYS(r). Product Information
   Google Scholar
• Milton Harris J, Martin NE, Modi M. Pegylation: a novel process for modifying paharmacokinetics. Clin Pharmacokinet 2001;40:539–51
   Google Scholar
• Glue P, Fang J, Rouzier-Panis R, et al. Pegylated interferon alpha-2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Clin Pharmacol Ther 2000;68:556–67
   PubMed Web of Science ®Google Scholar
• Formann E, Jessner W, Bennett L, et al. Twice-weekly administration of Peginterferon-alpha-2b improves viral kinetics in patients with chronic hepatitis C genotype 1. J Viral Hep 2003;10:271–6
   PubMed Web of Science ®Google Scholar
• Lamb MW, Martin NE. Weight-based versus fixed dosing of peginterferon (40kDa) alfa-2a. Ann Pharmacother 2002;36:933–5
   PubMed Web of Science ®Google Scholar
• Algranati NE, Sy S, Modi M. A branched methoxy 40 kDa polyethylene glycol (PEG) moeity optimizes the pharmacokinetics (PK) of pegIFN á- 2a (PEG-IFN) and may explain its enhanced efficacy in chronic hepatitis C (CHC). Hepatology 1999;30:190A
   Google Scholar
• McHutchison JG, Poynard T, Esteban-Mur R, et al. for the International Hepatitis Interventional Therapy Group. Hepatic HCV RNA before and after treatment with interferon alone or combined with ribavirin. Hepatology 2002;35:688–93
   Google Scholar
• Lindsay KL, Trepo C, Heintges T, et al. A randomised double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001;34:395–403
   PubMed Web of Science ®Google Scholar
• Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001;33:433–8
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. New Engl J Med 2000;343:1666–72
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, et al. Peginterfeon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958–65
   PubMed Web of Science ®Google Scholar
• Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New Engl J Med 2002;347:975–82
   PubMed Web of Science ®Google Scholar
• Hadziyannis S, Cheinquer H, Morgan T, et al. PegInterferon (PEGASYS) in combination with ribavirin (RBV): efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining the effect of duration of treatment and RBV dose. J Hepatol 2002;36(S1):3
   Google Scholar
• National Institutes of Health. Consensus Development Conference Statement Management of Hepatitis C. June 10-12, 2002
   Google Scholar
• Fried M, Schiffman M, Reddy K, et al. Peginterferon a 2a plus ribavirin for chronic hepatitis C virus infection. New Eng J Med 2002;347:975–82
   PubMed Web of Science ®Google Scholar
• Davis GL. Monitoring of viral levels during therapy of Hepatitis C. National Institutes of Health Consensus Development Conference Statement Management of Hepatitis C, June 10-12, 2002. Hepatology 2002;36:S145–51
   Google Scholar
• Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression. Hepatology 2002;36:S47–56
   PubMed Web of Science ®Google Scholar
• Ghany MG, Kleiner DE, Alter HJ, et al. Progression of fibrosis in early stages of chronic hepatitis C. Hepatology 2000;32:496A
   Google Scholar
• Marcellin P, Akremi R, Cazals D, et al. Genotype 1 is associated with a slower progression of fibrosis in untreated patients with mild chronic hepatitis. J Hepatol 2001;34(S1):159
   Google Scholar
• Zeuzem S, Diago M, Gane E, et al. International, multi-center, randomized controlled study for the treatment of patients with chronic hepatitis C and persistently normal ALT levels with peg-interferon alfa 2a and ribavirin. Hepatology 2003;38:208A
   Google Scholar
• Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New Engl J Med 1998;338:853–60
   PubMed Web of Science ®Google Scholar
• Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001;33:562–9
   PubMed Web of Science ®Google Scholar
• Goelz J, Klausen G, Moll A. Efficacy and tolerance of therapy with IFN-alpha/RBV and pegIFN-alpha/RBV in HIV-/HCV- coinfected IVDUs. Presented at the XIVth World AIDS Conference, Barcelona, Spain, 7-12 July 2002; abstr.MoPeB3258
   Google Scholar
• Pérez-Olmeda M, Núñez M, Romero M, et al. Pegylated interferon alpha 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003;17:1023–8
   Google Scholar
• Perronne C, Carrat F, Bani S. RIBAVIC trial (ANRS HC02): a controlled randomized trial of pegylated-inter-feron alfa-2b plus ribavirin versus interferon alfa2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients: preliminary results. Presented at the XIVth World AIDS Conference, Barcelona, Spain, 7-12 July 2002; abstra.LbOr16
   Google Scholar
• Hopkins S, Lyons F, Brannigan E, et al. Tolerability of pegylated interferon and ribavirin in the HIV/HCV co-infected population. Presented at the XIVth World AIDS Conference, Barcelona, Spain, 7-12 July 2002; abstra.ThPeC7531
   Google Scholar
• Cargnel A, Casella A, Angeli E, et al. Pegylated interferon alfa-2b (PEG-IFN) plus ribavirin versus PEG-IFN for the treatment of HIV/HCV co-infected patients: an open, multicentre, randomized trial. Presented at Digestive Disease Week, San Francisco, 2000;abstra.115
   Google Scholar
• Perronne C, Carrat F, Bani-Sadr F, et al. Final results of ANRS HCO2-Ribavic: a randomised controlled trial of pegylated - interferon a2b and ribavirin vs interferon a2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 8-11 February 2004; abstra.117LB
   Google Scholar
• Torriani F, Rockstroh J, Rodriguez-Torres M, et al. Final results of APRICOT: a randomised, partially blinded, international trial evaluating peginterferon a2a (40kDa) (PEGASYS) and ribavirin versus interferon a2a and ribavirin in the treatment of HCV in HIV/HCV coinfection. Presented at the 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, USA, 8-11 February 2004; abstra.112
   Google Scholar
• EASL International ConsensusConference on Hepatitis B. J Hepatology 2003;39:S3–25
   Google Scholar
• Cooksley WGE, Piratvisuth T, Wang Y, et al. 40 kD peginterferon alfa-2a (PEGASYS): Efficacy and safety results from a phase II, randomised, actively-controlled, multicenter study in the treatment of HBeAg positive chronic hepatitis B. Hepatology 2001;34:349A
   Google Scholar